SCHEMBL6972669

SCHEMBL6972669

COC(=O)c1ccc(/C(N)=N/O)s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 2/20 0.50
▸ LMNA P02545 2/20 0.50
▸ PPARG P37231 1/20 0.50
▸ NCOA2 Q15596 1/20 0.50
▸ NCOA1 Q15788 1/20 0.50
▸ NCOA3 Q9Y6Q9 1/20 0.50
▸ HPGD P15428 6/20 0.45
▸ L3MBTL1 Q9Y468 3/20 0.45
▸ ATM Q13315 3/20 0.45
▸ MAPK1 P28482 2/20 0.45
▸ TSHR P16473 2/20 0.45
▸ TDP1 Q9NUW8 1/20 0.40
▸ ALDH1A1 P00352 7/20 0.37
▸ KDM4E B2RXH2 3/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ MRGPRX4 Q96LA9 1/20 0.37
▸ OPRD1 P41143 1/20 0.36
▸ MAPT P10636 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL70027 0.82 NPSR1 (0.67) NPSR1LMNAPPARGNCOA2NCOA1
SCHEMBL2226398 0.81 HDAC3 (0.56) LMNAHPGDL3MBTL1MAPK1TSHR
SCHEMBL14672143 0.81 HDAC3 (0.56) LMNAHPGDL3MBTL1MAPK1TSHR
SCHEMBL2226393 0.81 HDAC3 (0.56) LMNAHPGDL3MBTL1MAPK1TSHR
SCHEMBL28643715 0.81 NPSR1 (0.56) NPSR1LMNAPPARGNCOA2NCOA1
SCHEMBL17065270 0.81 DAO (0.47) HPGDALDH1A1KDM4ERAB9AMEN1
SCHEMBL17065272 0.81 DAO (0.47) HPGDALDH1A1KDM4ERAB9AMEN1
SCHEMBL2407264 0.80 NPSR1 (0.51) NPSR1LMNAPPARGNCOA2NCOA1
SCHEMBL2407263 0.80 NPSR1 (0.51) NPSR1LMNAPPARGNCOA2NCOA1
Hydrochloric Acid SCHEMBL27199218 0.78 NPSR1 (0.53) NPSR1LMNAPPARGNCOA2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2533783-B1 COMPOUNDS AND METHODS for the inhibition of HDAC TEMPERO PHARMACEUTICALS INC (US) 2015-11-04 — — EP disclosed
US-20150038534-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2015-02-05 — — US disclosed
US-8901156-B2 Compounds and methods TEMPERO PHARMACEUTICALS, INC. (US) 2014-12-02 — — US disclosed
US-20130059883-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2013-03-07 — — US disclosed
WO-2011088181-A9 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2013-01-31 — — WO disclosed
WO-2011088181-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2011-07-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038534-A1 COMPOUNDS AND METHODS XDH, LPXN, CCNY NPSR1 254/4885LMNA 26/4885PPARG 2431/4885
US-20130059883-A1 COMPOUNDS AND METHODS XDH, LPXN, CCNY NPSR1 254/4885LMNA 26/4885PPARG 2431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback